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                                           INTRODUCTION 
          Insulin resistance is defined as an impaired ability of plasma 
insulin at usual concentrations to adequately promote peripheral glucose 
disposal, suppress hepatic glucose output and inhibit very low density 
lipoprotein (VLDL) output. 
 Insulin resistance results in compensatory increase in insulin 
secretion. The resulting hyperinsulinemia overcomes the insulin 
resistance for sometime and keeps the blood sugar in normal range. 
However when relative beta cell insufficiency (insulin secretion 
insufficient for the level of hyperglycemia) also sets in, overt diabetes 
develops. 
 Metabolic syndrome also known as Syndrome X  is associated 
with increased risk of coronary heart disease and stroke. The features of 
metabolic syndrome include abdominal obesity, hyperinsulinemia, 
dyslipidemia, type 2 diabetes mellitus, and hypertension1. The core 
feature is elevated insulin levels which develops early in the course of 
disease. 
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 It is increasingly being recognized that Indians are an ethnic 
group at high risk for insulin resistance. In a 1998 publication,  WHO 
has predicted that India would experience the largest increase in type 2 
diabetes mellitus in the next 25 years and would have the greatest 
number of diabetic individuals by the year 20253. 
 According to a large body of epidemiological data from many 
parts of world, the seeds of insulin resistance are sown during prenatal 
life itself. Low birth weight and more so intra uterine growth  
retardation followed by rapid catch-up growth and relative postnatal 
obesity have been shown to be associated with insulin resistance4,5. 
According to Barker et al, low birth weight acts as a surrogate marker 
for poor gestational environment and there is inverse relationship 
between birth weight and insulin resistance later in life. 
 In addition to insulin resistance, tracking of other cardiovascular 
risk factors such as obesity, physical inactivity, hyperlipidemia, and 
hypertension is seen from childhood through adolescence to adulthood. 
Therefore the steps for the prevention of insulin resistance and other 
cardiovascular risk factors should ideally be initiated during childhood. 
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Clinical features of insulin resistance syndrome 
 The clinical phenotype of insulin resistance includes centrally 
biased obesity; characteristic skin involvement (acanthosis nigricans, 
skin tags, striae, acne, hirsutism, and frontal balding); an allergic 
diathesis, especially as manifested by asthma; hypertension; an 
atherogenic dyslipidemia increased VLDL with raised triglycerides  and 
reduced levels of the protective high density lipoprotein (HDL) 
cholesterol; early atherosclerosis, tall stature and pseudoacromegaly 
(with suppressed growth hormone levels); focal segmental 
glomerulosclerosis; hepatic steatosis; and adrenal and ovarian 
hyperandrogenism (Table-1). Importantly, insulin resistance is not 
infrequent in the absence of obesity, whereas even considerably obese 
persons can be insulin sensitive.  
 Obese patients represent heterogeneous subgroups of metabolic 
and phenotypical expressions of insulin resistance, whereas individuals 
with the same Body Mass Index (BMI) can have varying degrees of  
insulin resistance and metabolic compensation. However, most 
individuals with BMI more than 35–40 kg/m2 are insulin resistant. 
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Table -1 
Features of IRS Pediatric features of IRS 
• Acanthosis Nigricans 
• White striae  
• Centrepetal obesity 
• Hirsutism, ovarian                         
hyperandrogenism and infertility  
• Dyslipidemia (↑TG,↓HDL) 
• Premature atherosclerosis 
• Hypertension 
• Hyperuracemia/gout 
• Allergies/asthma 
• Fatty liver (NASH) 
• Chronic pancreatitis 
• Focal glomerulosclerosis 
• Glucose intolerance 
• Type 2 diabetes 
• Increased cancer risk 
• Increased  incidence of 
Alzheimer’s disease 
• Positive family history of 
diabetes, obesity, hypertension, 
CHD, and/or stroke 
• History of maternal gestational 
diabetes 
• SGA (mostly) or LGA (less 
often) 
• Asthma/allergic rhinitis 
• Premature pubarche 
• Red (new) and white (old) striae, 
from adrenarche onward 
• Obesity appears or worsens at 
adrenarche 
• Decreasing resting energy 
expenditure 
• Low resting fat to carbohydrate 
oxidation   rates 
• Acanthosis Nigricans 
• Tall stature/pseudoacromegaly 
• Hirsutism/PCOS with 
adolescence 
• Adipomastia/gynecomastia 
• Acute pancreatitis 
• Premature atherosclerosis 
• Hypertension/glomerulonephritis 
• Type 2 diabetes 
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  Children with BMI higher than the 85th percentile for age and 
gender are classified as overweight, whereas those that are higher than 
the 95th percentile are designated obese6. Adolescents and adults with 
BMI of 25 kg/m2 or more are at risk for adiposity-related morbidity, 
whereas those with BMI greater than 30 kg/m2 are obese according to 
the WHO panel.  
PATHOGENESIS  
Nature vs. nurture. 
 The dramatic rise in obesity-associated  insulin resistance 
syndrome reflects environmental increased availability and consumption 
of food with high carbohydrate and fat contents together with decreased 
physical activities. Genetic predispositions to obesity favor selection of 
metabolically advantageous (energy thrifty) traits resulting in an 
enhanced ability to store excess calories in tissues as fat and to spare 
protein breakdown for gluconeogenesis, favoring survival in times of 
hunger. Genotypic factors influence the ability to use food energy 
efficiently through mechanisms of intra abdominal fat distribution, 
resting metabolic rate, changes in energy expenditure, body composition 
to overfeeding, feeding behavior (including food preferences), adipose 
tissue lipoprotein lipase activity, and the basal rate of lipolysis.  
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Genes involved in  insulin resistance  
 The pathogenesis of insulin resistance is multifactorial. Thus, 
several molecular pathways in energy homeostasis, lipid metabolism, 
insulin receptor signaling pathway, cytokines, hormone-binding proteins 
including those that are serine protease inhibitors (SERPINS), and other 
protease regulators are responsible for the development of insulin 
resistance, obesity, or lipodystrophy. In the energy homeostasis 
pathway, uncoupling proteins, leptin-proopiomelanocortin (POMC), 
ghrelin-neuropeptide Y (NPY), and sympathetic nervous system 
regulation pathways are important. In the insulin-signaling pathway, 
mutations in insulin receptors, development of insulin receptor  
auto-antibodies, and defects in plasma cell membrane glycoprotein-1 
and glucose transporter 4 (GLUT4) molecules are reported. In the lipid 
homeostasis pathway, adipocyte-derived hormones, leptin, adiponectin, 
resistin, peroxisomal proliferator-activated receptor-γ (PPAR- γ ) and 
PPAR-α are variously involved, as are lipoprotein lipase and genes 
responsible for adipose tissue formation. Increased availability of free 
fatty acids (FFAs) to muscle provokes insulin resistance. Proteases 
contributing to the development of diabetes are represented by CAPN 10 
and prohormone convertase deficiencies.  
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Acquired insulin resistance  
 Insulin receptor antibodies, Cushing’s syndrome, glucocorticoid 
steroid therapy, acromegaly, hyperparathyroidism, and exogenous 
obesity can all produce insulin resistance. In practice, however, steroid-
induced insulin resistance in a person who happens to be genetically 
prone to insulin resistance is the most commonly encountered, 
especially when the obese child also has insulin resistance-associated 
asthma. GH therapy can provoke transient insulin resistance. In the 
small for gestational age (SGA) disorders without catch-up growth, such 
as the Russell-Silver syndrome, insulin resistance may develop even 
before GH is given.  
Birth weight and length.  
 An increased incidence of adulthood diseases, such as 
cardiovascular diseases, type 2 diabetes, and hypertension, is noticed in 
small for gestational (SGA) babies. Insulin resistance is particularly 
apparent when an SGA newborn undergoes rapid postnatal weight gain. 
The Early Bird Study suggested that insulin resistance at 5yrs was 
related not to birth weight, but, rather, to weight after  catch-up growth, 
especially in girls4. Such growth patterns following fetal growth restraint 
are associated with maternal-uterine factors such as primiparity, 
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smoking, restrictions in the maternal diet, maternal insulin resistance, 
and gestational diabetes (Fig-1). Alternatively, if an inherited insulin 
resistance state was manifested in utero, then diminished fetal growth 
with SGA might be anticipated, because insulin is a powerful prenatal 
growth hormone(Fig-2). Curiously, large for gestational age children are 
also at risk of insulin resistance as well. A U-shaped relation between 
birth weight and fasting insulin, BMI and fat mass has been 
established41,42.  
 Gestational diabetes per se significantly increases the subsequent 
risk of obesity and type 2 diabetes10. 
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FIG-1 
THRIFTY PHENOTYPE HYPOTHESIS 
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 Schematic representation of the thrifty phenotype hypothesis, 
showing the vital role of fetal nutrition in the development of the 
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FIG .2. 
THE FETAL INSULIN HYPOTHESIS 
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Insulin resistance, leptin resistance, ghrelin, and satiety 
 The insulin/leptin-arcuate nucleus of the hypothalamus axis 
regulates energy homeostasis through control of appetite and energy 
expenditure. Both hormones rise in direct proportion to adipose mass; 
they cross the blood-brain barrier and have receptors in the arcuate 
nucleus. Leptin acts on POMC (pro opio melanocortin) expression and 
α-MSH (melanocyte stimulating hormone) release. α-MSH in turn, 
interacts with MC3/4R (melanocortin 4 receptor) to reduce food intake 
and increase energy expenditure by activating the sympathetic nervous 
system. Leptin down-regulates anabolic NPY(neuro peptide Y), agouti-
related peptide (AGRP), orexins, and melanin-concentrating hormone in 
the hypothalamus. The central melanocortin system is a key mediator of 
the catabolic effects of insulin in the brain. Gastric secretion of ghrelin is 
increased by fasting and increases pituitary GH release, thereby 
stimulating lipolysis to provide energy substrates. Ghrelin stimulates 
NPY-AGRP to antagonize α-MSH. The resultant lack of anorexic 
pressure on MC4Rs results in increased feeding behavior and energy 
efficiency (with reduced fat oxidation) to store energy as fat. 
Conversely, in the fed state, insulin and leptin levels are increased, 
which increases the synthesis and processing of hypothalamic POMC to 
its component peptides, including α-MSH, which, together with its 
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colocalized neuromodulator cocaine/amphetamine-regulated transcript, 
acts at the MC4R to decrease appetite. Insulin and leptin also directly 
inhibit NPY-AGRP, further limiting feeding and providing for 
unantagonized MC4R occupancy. Therefore, ghrelin, insulin, and leptin 
represent afferent hormonal links between peripheral energy metabolism 
and central feeding behavior and tie together the gut, pancreas, 
adipocyte, hypothalamus, and pituitary to form a coordinated growth and 
energy regulatory system11,12. 
Natural history of the clinical insulin resistance syndrome 
 The natural history of insulin resistance syndrome begins in 
childhood, from the interplay of genetic and environmental factors. 
Although it is generally unclear whether a primarily genetically encoded 
state of insulin resistance and/or satiety disorder appears first, insulin 
resistance results in hyperinsulinism and precocious development of 
atherosclerosis and type 2 diabetes13. The modern day diet from early 
childhood replete with large amounts of saturated fats and excess 
carbohydrates is probably important to the development of 
hyperinsulinemia and obesity. Dietary carbohydrates (and fats) induce 
hyperinsulinism, a reduction in fatty acid (FA) oxidation, and 
hypertryglyceridemia. Diets rich in saturated FAs add a strong 
insulinotropic effect. In children, obesity and insulin resistance precede 
the development of hyperinsulinism. The hyperinsulinemia can thus be 
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seen as a compensatory mechanism for the preexisting, genetically 
programmed insulin resistance which represents a mechanism for 
protection against the development of impaired glucose tolerance and 
diabetes.  
 Insulin hyper secretion (especially portal) leads to increased free 
fatty acid synthesis, especially in the liver and adipose tissue. A 
compensatory increase in glucose oxidation and increased malonyl 
coenzyme A signaling in the face of abundant fatty acids directs  
diversion away from ß-oxidation to compensatory increases in long-
chain fatty acids and triglycerides synthesis in the liver. Normally 
appetite can be suppressed by both leptin and insulin; however, diets 
high in fat stimulate appetite directly. The liver, in turn, becomes 
insensitive to compensatory leptin signaling to increase ß-oxidation, 
which is blocked in insulin resistance state, because of high levels of 
malonyl CoA. Elevated levels of malonyl CoA block fatty acid ß- 
oxidation, leading to triglyceride accumulation in muscle and liver, with 
impaired serine phosphorylation of insulin receptor substrate-1, 
decreased GLUT4 translocation, and thereby decreased glucose 
oxidation. In the pancreatic islets, these events lead to activation of 
caspases and increased ceramide levels inducing apoptosis of ß-cells. 
Type 2 diabetes thus results when there is insufficient insulin secretion 
to counter preexisting insulin resistance. 
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FIG.3 
CLINICAL FEATURES OF IRS WITH NATURAL HISTORY 
Infancy                                    
FH of obesity & type 2 diabetes                                                
SGA & LGA                                 Childhood  
Gestational diabetes 
                          Acanthosis nigricans                             Adolescence 
                        Premature adrenarche 
                           Obesity, Pseudo acromegaly 
                                Striae, Skin tags,Amenorrhea                                                    Adulthood 
                                           Tall stature,       Pseudo acromegaly 
                                                 Fatty liver, Focal glomerulosclerosis 
                                                                Hirsutism, ovarian hyperandrogenism, PCOS  
                                                                          Increased carotid wall thickness,Stroke, CHD 
                                                                                               Glucose intolerance, type 2 diabetes 
 
 
 
 
                                                                         
  22
FIG. 4 
LABORATORY FEATURES OF INSULIN RESISTANCE WITH 
NATURAL HISTORY 
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                                                          Increased decompensated insulin resistance               Adulthood 
                                                                                           Postprandial hyperglycemia 
                                                                                                      Fasting hyperglycemia 
                                    Diabetes 
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 Loss of first phase insulin response to predict development of 
diabetes  
 Children affected by insulin resistance are usually 
hyperinsulinemic individuals in whom carbohydrates can induce a 
delayed, but excessive, rise in insulin secretion14. This may cause an 
excessive fall in glucose levels 3–4 h later, of sufficient severity to 
provoke symptoms of hypoglycemia (late reactive hypoglycemia). As 
the  ability  to secrete insulin declines, postprandial glucose intolerance 
appears, followed by fasting hyperglycemia and diabetes.  
Hyperinsulinism and insulin resistance are not benign, even without 
diabetes  
           The majority of persons with insulin resistance will not develop 
type 2 diabetes. Insuin resistant individuals who can compensate by 
hyperinsulinemia may escape diabetes, but are still prone to other 
complications, such as early atherosclerosis, progression of obesity 
(especially central type), acanthosis nigricans, increased skin tags, 
hypertension, dyslipidemia, hypercoagulation, polycystic ovarian 
syndrome, fatty liver infiltration, focal segmental glomerulosclerosis, 
and an increased cancer rate as well15. Thus insulin resistant syndrome is 
not benign even when diabetes does not develop.  
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HYPERINSULINISM AND INSULIN RESISTANCE 
ASSOCIATED PATHOLOGIES                        
Adipose Tissue 
 It is widely believed that obesity itself, especially increased 
visceral fat accumulation, can lead to insulin resistance16.  Genetically 
induced insulin resistance can be the primary mechanism underling and 
evoking the progression of obesity. In contrast, non-obese lean 
individuals can develop insulin resistance also. It has been shown that 
lean sisters and brothers of patients with obesity complicated by insulin 
resistance and polycystic ovarian syndrome can have insulin resistance, 
confirming that insulin resistance can be a primary mechanism.  
Visceral fat  
                Visceral fat is a potent modulator of insulin action on hepatic 
glucose production17.Central distribution of body fat (waist/hip ratio, 
>0.90 in females and >1.0 in males) is associated with an increased risk 
of stroke, CHD, diabetes, and early mortality and is a more sensitive 
indicator of impending morbidity than absolute fat mass. Waist 
circumference correlates with cardiovascular morbidity as well as BMI. 
Leptin levels are higher in subcutaneous fat and show greater 
correlations with subcutaneous adiposity than with visceral adiposity18. 
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Visceral fat tissue, through its portal drainage, is an important source of 
free fatty acids that increase hepatic lipogenesis and decrease glucose 
oxidation.In comparison with subcutaneous fat,visceral fat has more 
glucocorticoid receptors and higher local concentrations of 
glucocorticoids. Omental adipose tissue contains significantly more 11ß-
hydroxysteroid dehydrogenase type 1 (11ßHSD1) activity than 
subcutaneous adipose tissue19, promoting increased cortisol production 
from conversion of inactive cortisone. Growth Hormone (and/or IGF-I) 
was suggested recently to inhibit 11ßHSD1, whereas in obesity, GH 
levels are decreased, leading to higher 11ßHSD1 activity20.  11ßHSD1  
activity correlates with insulin resistance21.  A local increase in 
glucocorticoid hormone action in visceral fat may contribute to the 
pathogenesis of key features of the metabolic syndrome. Increased 
abdominal striae and biochemically increased urinary free cortisol levels 
in obesity are observed.  
 Patients with Cushing’s syndrome have high levels of serum 
cortisol, and the patient with insulin resistance syndrome has low to 
normal levels, though both have increased levels of urinary free cortisol. 
The explanation lies in the decreased levels of corticosteroid-binding 
globulin (CBG) found in insulin resistance syndrome, where circulating 
cortisol is disproportionately free and bioactive, with increased 
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conversion of cortisone to the metabolically active cortisol. The clinical 
distinction between patients with Cushing’s and IRS is that the former is 
invariably growth retarded, in contrast to the child with insulin 
resistance syndrome in whom linear growth is excessive.  
Fatty liver or hepatic steatosis.  
 Hepatic steatosis is another complication of  insulin resistance 
that may progress over years with inflammation and fibrosis 
(nonalcoholic steatohepatitis). In adult patients with diabetes and 
obesity, 100% have mild steatosis, 50% have steatohepatitis, and 19% 
have cirrhosis22 .The disease is usually silent over many years. Serum 
levels of alanine aminotransferase, aspartate aminotransferase, alkaline 
phosphatase, and  γ-glutamyltransferase are elevated and have been 
proposed as surrogate markers of hepatic fat accumulation23 . The ratio 
of aspartate aminotransferase to alanine aminotransferase is usually less 
than 1, but this ratio increases as fibrosis advances.  
Hypertension 
 Hyperinsulinemia can increase blood pressure by several 
mechanisms: via its effect to increase renal sodium absorption, via 
increased activity of the sympathetic nervous system, and via FFA-
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induced sensitivity to adrenergic stimuli and antagonized nitric oxide 
vasorelaxation24.    
Insulin resistance as an initiator of atherosclerosis.  
 Studies of adults have shown that there is an association between 
insulin resistance and atherosclerosis. Increased thickness of the arterial 
carotid wall and an atherogenic dyslipidemic profile  compounded by 
low SHBG levels are factors for increased risk of atherosclerosis.  
 Importantly, hyperinsulinemia is an independent cardiovascular 
risk factor25.The most predictive childhood risk factor was increased 
BMI. Coronary artery calcifications were also associated with increased 
blood pressure and decreased HDL cholesterol levels measured during 
childhood26.  Fatty streaks can be found in the aorta in children older 
than 3 yr of age and in coronary arteries by adolescence27.  The 
Pathobiological Determinants of Atherosclerosis in Youth study 
confirmed the origin of atherosclerosis in childhood, showed that 
progression toward clinically significant lesions may occur in young 
adulthood, and demonstrated that the progression of atherosclerosis is 
strongly influenced by CHD risk factors28. 
 The thickness of the carotid wall, a validated surrogate marker for 
atherosclerosis in teenagers and young adults, is sensitive to the intake 
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of cholesterol, serum levels of cholesterol and triglycerides, BMI, 
smoking, hypertension, and fasting glucose29. 
 Endothelial dysfunction is an early event preceding the formation 
of plaques, representing an early disease process of atherosclerosis that 
begins in childhood and is associated with insulin resistance and 
hyperinsulinemia30. 
Low hormone-binding proteins and SERPINS.  
 Sex Hormone Binding Globulin(SHBG) has been found to be 
negatively correlated with BMI and fasting insulin levels. Decreased 
SHBG increases testosterone bioavailability, leading to the development 
of hyperandrogenism, even when serum levels of testosterone are 
normal. 
 SHBG is a ß-globulin produced by liver. SHBG is also referred to 
as testosterone-binding globulin (TeBG) or sex steroid binding protein 
(SBP). SHBG is present in plasma as 100-kDa heterodimer of variable 
glycosylated subunits31. In normal men about 50% of circulating 
testosterone is bound to SHBG (Fig.5). The normal range of  
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                                      FIG. 5 
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The free fraction represents 1% to 4% of the total testosterone. When the level of SHBG 
is reduced , as in obesity, the total testosterone is low, but bioavailanble and free 
testosterone levels are generally normal. 
 
 Sex hormone binding globulin level is 10 to 50 nmol/L, for men, 
45 to 90 nmol/L for children, and 30 to 90 nmol/L for women. Aging 
and various medical disorders alter plasma levels of SHBG. 
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                                           TABLE-2 
CONDITIONS WITH ABNORMAL SEX HORMONE BINDING 
GLOBULIN CONCENTRATIONS 
            INCREASED             DECREASED 
• Aging • Hyperinsulinemia 
• Androgen deficiency • Obesity 
• Estrogen treatment • Androgen treatment 
• Thyrotoxicosis • Hypothyroidism 
• Alcoholic cirrhosis • Hypercortisolism 
• Hepatitis • Nephrotic syndrome 
• Growth hormone 
deficiency 
• Acromegaly 
 • Familial 
 IGFBP-1 is often strikingly depressed in IRS, producing an 
excessive of free IGF-I.  This can lead to the development of 
microvascular complications and pseudoacromegaly. It is found that low 
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levels of IGFBP-1 are associated with the severity of IR, whereas 
IGFBP-3 correlates directly with the degree of hyperinsulinism.  
 The low levels of CBG found in IRS lead to disproportionately  
free and active circulating cortisol. That can lead to clinical and 
metabolic overlap between Cushing’s syndrome and IR. Increased 
conversion of inactive cortisone to active cortisol by 11ßHSD1 in 
visceral fat compounds the effect. CBG secretion has been shown to be 
negatively regulated by both insulin and IL-633. 
 Thyroid binding globulin levels in insulin resistance are often 
depressed, leading to confusion as to the presence of hypothyroidism. 
Obese patients are thus often unnecessarily treated for hypothyroidism 
that they do not have.  
 Cortisol Binding Globulin (CBG), thyroid binding globulin, and 
plasminogen activator inhibitor-1 (PAI-1) belong to a family of 
SERPINS (serine protease inhibitors). These binding proteins (serine 
protease inhibitors) are substrates for elastase that is expressed at the 
surface of neutrophils.  Increased peripheral white blood cell count and 
neutrophils are usually found in both obesity and insulin resistance, 
which might facilitate serine protease availability and binding protein 
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cleavage. This mechanism is likely to contribute to decreased serum 
binding globulins levels in obesity and insulin resistance.  
Inflammation, asthma, eczema, and impaired immunity.  
 Insulin resistance syndrome and type 2diabetes have increased 
markers of inflammation, such as C-reactive protein (CRP), erythrocyte 
sedimentation rates, and TNF-α levels. BMI correlates with levels of 
CRP34, and adiposity has been reported to be the major determinant of 
CRP levels in children. Leptin has  been shown to up-regulate the 
production of proinflammatory cytokines, including TNF-α and IL-6, to 
increase phagocytosis by macrophages, and to increase T helper cell 
type 1 (Th1) levels and suppression of Th2 cytokine production  
 Significant association between asthma and obesity has been 
noted, especially during puberty. One of the possible mechanisms is that 
obesity represents a proinflammatory state, and leptin levels influence 
Th1 cytokine responses. BMI correlated with the prevalence of asthma 
in both boys and girls. It was noted that girls who became obese between 
ages 6–11 yr were 7 times more likely to develop new asthmatic 
symptoms at ages 11–13 yr35. 
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Hypoventilation and sleep apnea.  
 Excess body fat leads to a decline in the expiratory reserve 
volume, vital capacity, total lung capacity, and functional residual 
volume, probably due to the excess body mass, though others implicate 
excessive leptin levels36. 
Acanthosis Nigricans (AN)  
 AN is a skin lesion that is widely used as a clinical surrogate of 
laboratory-documented insulin resistance/hyperinsulinemia, denoting a 
subgroup with a high risk for type 2 diabetes. The common sites of 
involvement include  axillae, posterior region of the neck, antecubital 
fossae, and groins. Less commonly, it involves the other flexural areas, 
umbilicus, submammary region, knuckles, elbows, and, in extreme 
cases, the entire skin. The severity of AN correlates well with the degree 
of insulin responses to insulin resistance. AN usually precede insulin 
resistance documentable by oral or intravenous glucose tolerance test. 
However, AN also persists into the decompensated phase of  insulin 
resistance where insulin levels may be normal or low.  
 High levels of insulin  acting on both insulin and IGF-1 receptors 
present on  keratinocytes and elevated levels of TNF-α and IFN-γ 
inducing up-regulation of PPARβ/δ result in keratinocyte proliferation36. 
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Hyperandrogenism and reproductive abnormalities  
            Insulin resistance can present with overt virilization or hirsutism, 
menstrual  irregularity, persistent acne, scalp hair loss, hyperhydrosis, 
infertility, or precocious adrenarche in childhood. Menstrual irregularity 
and evidence of hyperandrogenism   are associated with the  polycystic 
ovarian disease. Hyperinsulinemia potentiates ovarian hyperandrogenism 
by enhancing pituitary LH secretion, potentiating ovarian 17-
hydroxylase and 17,20-lyase activities, and suppressing blood SHBG 
and CBG levels and inhibiting both estradiol- and T4-stimulated SHBG 
production37. 
Pseudoacromegaly  
         Linear and acral growth is usually accelerated in insulin resistance 
and may present as pseudoacromegaly. Hyperinsulinemia promotes 
linear growth by activating skeletal IGF-I receptors, whereas low levels 
of IGFBPs can promote IGF-I action by allowing it to be freely and 
metabolically available. Ghrelin is known to stimulate GH secretion, and 
in obesity ghrelin levels are decreased. Direct action of leptin on bone 
growth can predispose to pseudoacromegaly38. Pseudoacromegaly is 
seen in the face of low plasma GH levels secretion so typical for obesity. 
Leptin decreases GHRH receptor gene transcription, thereby reducing 
GH levels and reduces responsiveness to GHRH .  
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Others  
            Additional complications include focal (IgA type) segmental 
glomerulosclerosis, uric acid elevation, cholelilthiasis, pseudotumor 
cerebri, Blount’s disease, slipped capital femoral epiphysis, and 
psychological problems.  
MEASURING INSULIN ACTION IN VIVO 
             Insulin resistance  is defined as an impaired ability of plasma 
insulin at usual concentrations to adequately promote peripheral glucose 
disposal, suppress hepatic glucose, and inhibit very low density 
lipoprotein (VLDL) output, but it can be inferred on strong clinical 
evidence and confirmed by insulin and glucose measurements made by 
fasting insulin/glucose screening, oral glucose tolerance tests (OGTT), 
the minimal model frequently sampled iv glucose tolerance test 
(FSIVGTT), and insulin/glucose clamp studies. Fasting levels of insulin 
greater than 15 µU/ml, or insulin peak (post-OGTT) levels of more than 
150 µU/ml and/or more than 75 µU/ml at 120 min of OGTT are 
hyperinsulinemic levels, which infer insulin resistance2,39. 
            In normal individuals ingestion of a meal increases glucose and 
other secretogogues, including glucagons-like peptide 1(GLP1), which 
act in concert to stimulate insulin secretion.  Hyperinsulinemia in turn 
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acts to renormalize the plasma glucose level by suppressing glucose 
production and increasing glucose utilization. Thus this ‘closed loop’ 
feed back system regulates plasma glucose concentration. In states of 
insulin resistance, the elevated insulin levels will be less able to 
normalize the glucose , therefore resulting in secondary stimulus to the  
β-cells and hyperinsulinemia. However, β-cell over secretion could also 
account for postprandial hyperinsulinism. Because of the closed-loop 
relationship between insulin secretion and insulin action it is 
problematic to infer the existence of insulin resistance directly from a 
‘closed loop' procedure like oral glucose tolerance test (OGTT). 
Hyperinsulinemic-euglycemic clamp technique 
           This technique uses an external feedback control to ‘open the 
loop’ between insulin secretion and sensitivity. By maintaining 
euglycemia endogenous insulin secretion by pancreas is effectively 
‘clamped’40. 
Procedure: After over night fasting venous catheters are inserted in 
right and left arms and 3 samples of blood to measure the basal insulin 
and glucose are taken at 5 min interval. The insulin infusion was started 
at a rate of 1mU/kg/min and continued for 3   hours. The starting time is 
marked as ‘0’. An infusion of 20% glucose was started at time 0. The 
                                                                         
  37
plasma glucose level is measured at every 5 minutes and glucose 
infusion is adjusted to maintain euglycemia at 5.6mmol/L. Insulin levels 
are measured usually after 2 hours of study at 140, 160, and 180min. 
Usually it takes at least 2 hours to attain steady state of euglycemia. The 
rate of glucose infusion is considered a reflection of insulin sensitivity. 
              The glucose clamp-derived index of insulin sensitivity   
(SIclamp)=M/(G*∆I) 
M- The steady state of glucose infusion (mg/min) 
G- The steady state blood glucose concentration (mg/dl) 
∆I- The difference between basal and steady state plasma insulin     
concentration (microunits/ml) 
 SIclamp  is usually expressed per kg body weight, per unit of surface area, 
or per unit fat free mass.    
Modified minimal frequently sampled intravenous glucose tolerance 
test: 
 In the normal 24-h day the insulin-sensitive tissues are never 
exposed to steady-state conditions. After a meal, glucose and insulin 
levels are changing, the rate of glucose uptake lags in time behind the 
time courses of glucose and insulin.  It may be preferable to measure 
insulin action from a dynamic relationship between glucose, the primary 
nutritive carbohydrate, insulin, the primary anabolic hormone, and the 
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rate of glucose disposition. One approach to such a measurement is the 
frequently sampled intravenous glucose tolerance test with ‘minimal 
model’. Minimal model is a computer model that simply represents the  
plasma dynamics in a compact and accurate package41. 
Procedure : After 12 hours of fasting, 2 vascular accesses obtained by 
inserting 2 flexible indwelling intravenous catheters through both 
antecubital veins. One is used for insulin administration; the other is 
used for glucose administration. Three samples of blood drawn for 
measuring fasting insulin and glucose at 10 min interval. Glucose in the 
form of 25% dextrose is administered intravenously over one minute 
period at a dose of 0.3g/kg. After 20 min insulin is administered in the 
dose of 0.03u/kg. In next 3 hour period 30 blood samples are drawn for 
estimation of glucose and insulin at frequent intervals. These values are 
entered into MINMOAD computer programme  (e.g- version 3,Richard 
N.Bergeman 1994) to evaluate the following: 
• First phase insulin release (AIRglucose): reflects β cell functionality.  
• Insulin sensitivity index (Si) : Reflects ability of insulin to 
enhance effect of glucose to normalize its own concentration after 
injection.  
•  Disposition index ( DI): Equals Si  times AIRglucose. It reflects 
insulin sensitivity normalized to the degree of insulin resistance. 
                                                                         
  39
    On the basis of intravenous glucose tolerance testing, insulin release 
consists of two phases14. In individuals with type 2 diabetes, the second 
phase response is diminished, and the first phase response is almost 
absent. However, the first phase response decreases long before the 
development of type 2 diabetes. AIR predicts the development of 
diabetes at a time when many subjects still have normal glucose 
tolerance. The DI is an excellent method to detect latent ß-cell defects, 
though hyperinsulinism documented by a high AIR is a predictor of the 
rate of increased fat mass.  
Surrogate Measures of Insulin Sensitivity:  
 Both hyperinsulinemic-euglycemic clamp technique and 
frequently sampled intravenous glucose tolerance test are time 
consuming, invasive, expensive, labor intensive, requires experienced 
personnel, and technically difficult to perform in obese young 
individuals. Here arises the need for simple but accurate methods for use 
in large populations. Indices of insulin sensitivity derived from fasting 
plasma glucose and insulin (HOMA-IR,QUICKI,FGIR, and fasting 
insulin) correlate strongly with Si assessed by the frequently sampled 
intravenous glucose tolerance test in obese children and adults42. 
                                                                         
  40
Fasting Insulin:  
          There is curvilinear relationship between fasting insulin and insulin 
sensitivity. If insulin sensitivity is low, fasting insulin will be elevated. 
The fasting insulin concentration will not represent an accurate 
reflection of insulin sensitivity comparing individuals or groups for 
whom β- cell function is not identical. When we compare fasting insulin 
between normal individuals and individuals with impaired glucose 
tolerance, the latter group is not only insulin resistant, but characterized 
by a β-cell defect of at least 50%. 
Homeostasis model assessment index (HOMA-IR): 
           This is based on fasting insulin and fasting glucose values .This is 
calculated by following formula    
         Fasting glucose (mmol/L)×fasting insulin(µmol/ml)  
HOMA-IR= 
                                     22.5 
 In non diabetic individuals plasma glucose differs little compared 
to fasting plasma insulin levels. In non diabetic subjects HOMA-IR 
values are proportional to the fasting insulin concentration. HOMA-IR 
will not reflect insulin sensitivity accurately in nondiabetic subjects with 
differing β-cell function. 
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Quantitative Insulin Check Index (QUICKI):  It is equal to the 
inverse of the sum of the logarithms of fasting plasma glucose and 
fasting plasma insulin.                               
QUICKI=   1/ (log fasting insulin(micromol/ml)+log fasting         
glucose(mg/dl) ) 
          Despite the logarithmic transformation, QUICKI values exhibit 
nonlinear proportionality to fasting plasma insulin and may 
underestimate insulin resistance in a population with a latent decrease in 
β-cell function.  
 Fasting Insulin Glucose Ratio (FIGR): The fasting glucose-to-
insulin ratio has also been proposed as a useful estimate of insulin 
sensitivity. 
                             Fasting glucose (mg/dl) 
FIGR= 
       Fasting insulin (micromol/ml) 
 
 Insulin Sensitivity Based Upon the OGTT: There are insulin 
sensitivity indices based on oral glucose tolerance test like Stumvoll 
index and Matzuda index. It is clear that a correlation between proposed 
OGTT-derived indices and clamp-derived insulin sensitivity may exist. 
However, the OGTT-derived indices contain endogenous insulin 
response in their calculation and it can not be excluded that reported 
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correlations reflect islet cell response rather than insulin sensitivity. As 
OGTT-based methods reflect secretion rather than sensitivity, 
application of the OGTT methods to subjects with impaired β-cell 
secretory capacity(e.g., those with impaired glucose tolerance,type 2 
diabetes) would incorrectly underestimate insulin resistance as post load 
hyperinsulinemia would be reduced. Another limitation is poor 
reproducibility43. This is due to high day-to-day variability in 
gastrointestinal function (gastric functioning,absorption and G.I 
hormones). It is concluded that variations in OGTT can not be readily 
interpreted to reflect changes in insulin sensitivity but rather changes in 
gastric emptying, insulin secretion, etc. At this juncture, it may not 
possible to support the use of the OGTT for assessing insulin resistance. 
TREATMENTS 
 In children, insulin resistant is usually well compensated by 
hyperinsulinemia, but there may be progressive failure of compensation 
through puberty with rising glucose and triglyceride levels. Even 
compensated hyperinsulinemia can lead to numerous complications from 
fatty liver and atherosclerosis to increased cancer risk. It is thus 
increasingly obvious that this sequence of events will be most easily 
interrupted at the earliest phase of life i.e., during childhood. The child 
with insulin resistant syndrome should be aggressively treated by 
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involvement in an exercise program, such as walking or swimming for 
30–40 min most days of the week, because exercise provokes glucose 
entry into muscle without the involvement of insulin. Calorie and 
especially carbohydrate restriction is the key to reduce weight. However, 
where there is also an increased level of triglycerides, restriction of 
animal fats should be imposed. Fibrates may be required, especially 
when trigglycerides levels exceed 500 mg/dl, at which point acute 
pancreatitis and gall bladder disease become real risks. In this regard, 
behavioral therapy and metformin have been proven safe and effective 
in improving insulin sensitivity in pediatric patients44. Laparoscopic 
surgery as well has been shown to be effective in decreasing weight, 
dyslipidemia, and insulin resistance  in adults.  
 Family-based behavioral interventions for obese children are safe 
and useful treatments for pediatric obesity. These interventions have 
been associated with reductions in total cholesterol, increases in HDL 
cholesterol, reductions in insulin resistance, and return of ovulatory 
cycles45. 
 Metformin is the drug of choice for insulin resistance syndrome. 
Metformin has various mechanisms of action in insulin resistance. It 
enhances insulin binding to insulin receptor with augmented 
phosphorylation and tyrosine kinase activity of the receptor46. It is 
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effective even in cases of insulin receptor mutations. It increases 
peripheral utilization of glucose through potentiating the 
phosphoinositol 3-kinase after engagement of the insulin receptor, 
increasing translocation of the glucose transporters GLUT1 and GLUT4 
isoforms to cell membrane in different tissues; increases the activity of 
adenosine monophosphate kinase in muscle and liver. It increases 
IGFBP-1; decreases endothelin-1, a marker of vasculopathy; and 
decreases hepatic glucose output. Metformin down-regulates TNF-α 
expression and  uncoupling  protein-2 mRNA concentrations in liver, 
thus decreasing hepatic lipid biosynthesis. Metformin is safe for the 
treatment of  insulin resistance syndrome in pediatric patients47. 
 The PPAR-γ (thiazolidenediones) agonists are a group of ligand-
activated transcription factors that govern energy metabolism, cell 
proliferation, and inflammation48. PPAR-γ agonists are effective at 
insulin sensitization, but are less useful in supporting weight loss.  
Lipid-lowering agents 
         Fibrates lower triglyceride levels, as mediated through the PPAR-γ  
transcription factor, mainly in liver, where it has an important role in FA 
oxidation, gluconeogenesis, and amino acid metabolism. Pretreatment of 
endothelial cells with a PPAR-γ agonist (fenofibrate) reduced markers of 
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inflammation such as vascular cell adhesion molecule-1 expression, 
CRP, fibrinogen, PAI-1, and IL-6. Statins inhibit 3-hydroxy-3-
methylglutaryl-CoA  reductase, the rate-limiting enzyme synthesis of 
cholesterol. To compensate for decreased synthesis and to maintain 
cholesterol homeostasis, hepatocytes increase the expression of LDL 
receptors, which increases the uptake of plasma LDL, the main carrier of 
extracellular cholesterol, resulting in lower plasma LDL concentrations. 
Decreased plasma LDL levels reduce the progression of atherosclerosis 
and may even lead to the regression of preexisting atherosclerotic 
lesions. Statins have important immunomodulatory effects as well and 
are able to decrease the recruitment of monocytes and T cells into the 
arterial wall and inhibit T cell activation and proliferation49. 
Low doses of aspirin inactivate the enzyme cyclooxygenase, which 
catalyzes the conversion of arachidonic acid to prostaglandins G2 and 
H2. These prostaglandins are precursors of thromboxane, a potent 
platelet proaggregant and vasoconstrictor. Low doses of enteric coated 
aspirin is preferred. Aspirin may have a place in dyslipidemic children 
with insulin resistance syndrome prone to pancreatitis.  
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Surgery 
 Restrictive surgical procedures based on an adjustable silicone 
band placement around a stomach fundal pouch can create a functional 
partition of the stomach. Whereas restrictive procedures are effective in 
reducing intake of solid foods, high consumption of more liquid high 
calorie foods may prevent weight loss50. Intestinal bypass surgery in 
children should probably only be used only in cases of potentially life-
threatening complications such as sleep apnea.  
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AIM OF THE STUDY 
  
 To correlate the level of sex hormone binding globulin with level 
of insulin resistance and (or) hyperinsulinemia  in obese prepubertal 
children.  
                                                                         
  48
REVIEW OF LITERATURE 
 David E.Laaksonen et al51 assessed the association of low levels 
of testosterone and sex hormone binding globulin level with 
development of metabolic syndrome and diabetes in men. They 
followed 702 middle-aged Finnish men participating in a population – 
based cohort study. After 11 years of follow-up, 147 men had developed 
the metabolic syndrome and 57 men developed diabetes. Men with total 
testosterone, calculated free testosterone and SHBG levels in the lower 
fourth had several fold increased risk of developing the metabolic 
syndrome and diabetes. They concluded that low total testosterone and 
SHBG levels independently predict development of the metabolic 
syndrome and diabetes in middle aged men. 
 V.Jeya Gopal et al52 tried to assess the biological variability of 
total testosterone and SHBG in polycystic ovarian syndrome and to 
determine the use of SHBG as a surrogate marker of insulin resistance in 
PCOS. The PCOS group had higher testosterone, lower SHBG and 
greater HOMA-IR than controls. In contrast to HOMA – IR, the intra 
individual variation in SHBG was lower in PCOS group. This study 
showed that for patients with PCOS, SHBG is an integrated marker of 
insulin resistance that may be of use to identity insulin resistant 
individuals for targeted treatment with insulin sensitizing agents. 
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 Involving diabetic and non diabetic obese population, in a case-
contrtol study, V  Jeya Gopal et al53 demonstrated inverse relationship 
between SHBG concentration and HOMA-IR in the group with type 2 
diabetes and in control subjects. In type 2 diabetic group, SHBG 
concentrations were lower than those in control subjects. The intra 
individual variation of SHBG for the group with type 2 diabetes was 
similar to that seen in the control group. In contrast, the mean intra 
individual variation of serum insulin and HOMA-IR was significantly 
greater in the group with type 2 diabetes than in the control subjects. 
Although SHBG levels differed significantly between those with or 
without diabetes, the absolute mean difference was small; indicating that 
measurement of SHBG can not be used as a simple test for insulin 
resistance in diabetics. They concluded that a much larger study is 
required to investigate whether diagnostic cut off values for low SHBG 
concentrations and insulin resistance in type 2diabetes can be 
established. Without these parameters, the utility of a low SHBG 
concentration as a reflection of insulin resistance in type 2 diabetes will 
be for serial monitoring of insulin resistance in individuals on treatment 
after the presence of insulin resistance has been established by 
conventional means. 
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 Thus a relationship between hyperinsulinemia and decreased 
serum sex hormone binding globulin has been described in adults. Felix 
Gascon et al54 evaluated usefulness of SHBG as an index of 
hypertsulinemia and/or insulin resistance in obese children (aged 6-9 
yrs) of both sexes. They carried out a cross-sectional study of cases and 
controls. The obese group presented significantly elevated levels of 
insulin, and insulin / glucose ratio compared with control group. SHBG 
and testosterone levels were significantly lower than those in the non-
obese group. Fasting insulin, BMI and testosterone were inversely 
correlated with SHBG concentration. Multivariate analysis revealed 
insulin was the only independent predicting factor for serum SHBG 
concentration in obese group. They concluded that there is strong 
relationship between insulin and SHBG. Their data supported the role of 
insulin in the regulation of serum SHBG level. 
 PJ Galloway et al55 assessed the validity of SHBG as a potential 
marker for hyperinsulinemia / insulin resistance in prepubertal obese 
children. 25 obese children were studied; 14 Children were found to be 
hyperinsulinemic. The SHBG concentrations were below the sex related 
reference range in the hyperinsulinemic group. They concluded that a 
subnormal SHBG concentration in a prepubertal child is strongly 
predictive of hyperinsulinemia. By measuring the circulating SHBG 
concentration, it might be possible to identity those at risk of metabolic 
syndrome targeting them for lifestyle changes. 
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STUDY JUSTIFICATION 
Traditionally, hyperinsulinemic – euglycemic clamp technique 
and modified minimal model frequently sampled intravenous glucose 
tolerance test (FSIVGTT) are used to document the insulin sensitivity or 
resistance accurately. Both the procedures are time consuming, invasive, 
expensive, labour intensive, require experienced personnel and are 
technically difficult to perform in obese young people. 
Simple indices based on fasting insulin and glucose concentration 
have been developed. Homeostasis model assessment for insulin 
resistance (HOMA-IR), Quantitative insulin sensitivity check index 
(QUICKI), and fasting glucose-to-insulin ratio (FGIR), are 
epidemiologically useful insulin sensitivity indices. These indexes 
derived from fasting samples appear to be a valid tool for estimating 
insulin sensitivity on obese children adolescents42. 
There are certain limitations in using these fasting indices. In 
patients with impaired glucose tolerance and overt DM, the utility of 
these indices decrease especially that of HOMA-IR56. In overt type 2 
DM; large amounts of proinsulin relative to insulin are secreted. Routine 
insulin assays will yield falsely high values of insulin and thus make 
fasting indices less useful. After therapeutic intervention, on serial 
follow up of children, they are subject to repeated fasting to assess 
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insulin resistance. Even slight exertion or consumption of single toffee 
which are quiet unavoidable in young children at times can dramatically 
alter values fasting insulin indices. 
Hence there is a need for a surrogate marker of insulin resistance, 
which is reproducible, stable and easily measured. It would be 
invaluable for both research and clinical practice, particularly for 
following insulin-sensitizing therapy such as metformin and 
thiazolidinediones. 
 There is evidence that insulin is an important modulator of SHBG 
concentration. It is potent inhibitor of SHBG production and also 
reduces the stimulatory effect of 17 B-estradiol and thyroxine on SHBG 
production. 
 Reduced serum SHBG levels have been described in different 
insulin resistance states with hyperinsulinemia such as polycystic ovary 
syndrome52. 
 Some studies have proved that low SHBG concentration is an 
independent risk factor for non-insulin-dependent diabetes mellitus57. 
 In insulin resistant states unlike insulin and glucose 
concentrations, SHBG concentrations are stable and will not undergo 
short-term fluctuations. 
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MATERIALS AND METHODS 
Study Design: 
 Descriptive study. 
Study period : 
 Aug 2004 to March 2006 
Study place: 
        Pediatric Endocrine Division, Institute of Child Health & Hospital 
for Children, Chennai – 8. 
Inclusion Criteria: 
             Prepubertal obese children (Tanner stage I) aged move than 5 
years with Body Mass Index (BMI) falling above 95th percentile. 
Exclusion Criteria: 
 Secondary causes of obesity (e.g., Genetic syndrome Cushing 
syndrome, hypothyroidism, etc) Children on long term drug therapy 
especially with those drugs which are going to alter the body 
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composition (e.g.,, amphetamine, methylphenidate, growth hormone, 
etc). 
Sample Size 
 Based on two previous European studies conducted on children, 
for an α error of 0.05 and the power of study being 0.8 with 95% 
confidence interval, calculated sample size is 45 that was approximated 
to 50. The anticipated mean difference in SHBG is 15nmol/L.  The 
anticipated standard deviation is 20nmol/L.  
Maneuver 
 The subjects who were included in the study were admitted in 
General pediatric medical ward. After 12 hours of fast and bed rest, the 
following biochemical parameters were measured. 
1) Fasting plasma glucose 
2) Fasting insulin 
3) Sex hormone binding globulin  
 Plasma glucose was determined by glucose oxidase – peroxidase 
method in a automated analyzer. Plasma insulin levels were measured 
by ELISA immunoassay. Sex hormone binding globulin levels were 
estimated by chemiluminenece immunoassay. 
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 The HOMA-IR, QUICKI, and FGIR were derived as estimates of 
insulin resistance.  The HOMA index was calculated as fasting insulin 
concentration (μu/ ml) x fasting glucose concentration (mmol/L) / 22.5. 
The QUICKI was calculated as1/ [log fasting insulin concentration (μu/ 
ml) + log glucose concentration (mg/dL)]. FGIR is calculated as fasting 
glucose (mg/dl)/fasting insulin (μu/ ml). 
       Pearson correlation coefficient was calculated between SHBG and 
insulin resistant indices. Simple linear regression was constructed taking 
insulin resistant index as dependent variable and SHBG as independent 
variable. 
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RESULTS 
        50 obese prepubertal children were included in the study based 
on statistically calculated sample size. Though there was skewed 
distribution of fasting insulin level, none of them was overtly diabetic.  
FIG.6 
                      Sex distribution 
                 
 Of the total of 50 children studied, there were 27 males and 23 
females. 
 
          
 Males
54%
Females 
46% 
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FIG.7 
                              Age distribution 
 
 Number of cases registered in our obesity clinic increases along 
with increasing age. This diagram reflects inclusion criteria of the 
study whereby older children with signs of pubertal progression are 
excluded.  
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                                     FIG.  8 
CORRELATION BETWEEN SHBG & HOMO - IR 
                 
                              y = -0.1069x + 6.4796 
                                       R2= 0.4889 
                                       r  = -0.699214        p<0.01 
 There is significant negative correlation between HOMA-IR 
values and Sex Hormone Binding Globulin levels exhibiting non-
linear relationship at hyperinsulinemic levels. 
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                                      FIG. 9 
CORRELATION BETWEEN SHBG & FGIR 
                
                                y = 0.3627x - 1.3856 
                                 R2= 0.6491 
                                 r =0.805667             p<0.01 
 There is significant positive correlation between Fasting 
Glucose-Insulin Ratio and Sex Hormone Binding Globulin level. 
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                                             FIG. 10 
CORRELATION BETWEEN SHBG & QUICKI 
                         
 
                                              y = 0.0022x + 0.268 
                                              R2= 0.8515 
                                              r = 0.922768             p<0.01 
 There is positive healthy correlation between QUICKI values and 
Sex Hormone Binding Globulins. 
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FIG.11 
CORRELATION BETWEEN SHBG & FASTING 
INSULIN 
                 
                                 
     y = -0.409x + 26.07 
                                  R2= 0.5165 
                                r = - 0.718679            p<0.01 
 There is significant negative correlation between fasting insulin 
levels and Sex Hormone Binding Globulin levels which is nearly 
equivalent to the correlation established between HOMA-IR and SHBG. 
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DISCUSSION 
 The plasma SHBG concentration, originally considered to be 
under the direct regulation of sex hormone levels, is now considered to 
be under multi factorial regulation. Indeed, the basal production of 
SHBG seems to be steroid independent and more related to general 
metabolic factors and nutritional status58,59. In this sense some hormones 
such as growth hormone, insulin like growth factor (IGF)-I and insulin 
may play a more active role in the regulation of SHBG levels60. 
Recently, there has been increased interest in the role played by insulin 
in this multi regulation. It is now known that insulin has an inhibitory 
effect on synthesis of SHBG. 
 By using cultured HepG2 cells, it has been found that insulin is 
potent inhibitor of basal production of SHBG. This action may by a 
direct mechanism or  by indirectly increasing free fraction of IGF1. Any 
way, the relationship between insulin and SHBG is widespread 
phenomenon in adults61 and is present even in neonates62. Therefore, 
evidence suggests that it is a more physiological process than was 
originally thought63. Thus SHBG level could be a general marker for 
hyperinsulinemic insulin resistance. This would explain the observation 
that a low serum SHBG level is a strong predictor for development of 
NIDDM. 
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 Though numerous adult studies have already established negative 
correlation between insulin resistance and sex hormone binding globulin 
level, prepubertal period is ideal time to test the relationship. During 
pubertal progression, there are dynamic changes in the level of insulin 
resistance. Insulin resistance increased immediately at the onset of 
puberty (T2) but returns to near prepubertal level by the end of puberty 
(T5). Its peak occurs at T3 in both sexes64. Girls are more insulin 
resistant than boys at all pubertal stages. 
 More over SHBG level is also influenced by sex hormones. 
Androgens decrease SHBG level: estrogen increase SHBG level. 
Pregnancy, oral contraception and liver disease adversely affect the 
normal physiological levels of SHBG. Because of absence of sex 
hormone influence on SHBG, insulin alone has greatest impact on its 
secretion in prepubertal period. More over prepubertal children aged 
more than 5 years are more prone to develop simple obesity. Hence 
prepubertal period offers excellent opportunity to study correlation 
between SHBG and insulin resistant status among all age groups. 
 David E.Laaksonon51 et al showed that after adjustment for age, 
men with concentration of SHBG in the lower fourth were 1.7 – 2.8 
times more likely to develop the metabolic syndrome than other men 
during their 11 years follow up study of 705 adult males. They also 
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showed that after adjusting for age, men with SHBG concentration in 
lower fourth had increased risk of incidence of diabetes by 1.7 to 4.3 
fold. 
 Vijay JeyaGopal et al52 established an inverse relationship 
between SHBG concentration and HOMA-IR in the adult population of 
type 2 diabetes (r = -0.32, P – 0.001) and in control subjects (r = - 0.28, 
P – 0.003). 
 Vijay JeyaGopal et al53, in their study of 12 polycystic ovarian 
cases showed higher HOMA-IR in the PCOS group than in controls and 
established inverse relationship between SHBG concentration and both 
serum insulin (r = -0.24, P – 0.001) and HOMA – IR (r = -0.21,  
P= 0.001). 
 Very few studies have been conducted so far in children 
correlating SHBG level and Insulin resistance. Felix Gascon et al54 in 61 
obese children, showed the negative correlation between SHBG level 
and insulin (r = -0.4512, P - < 0.001). There was positive correlation 
between FGIR and SHBG (r = 0.4573, P < 0.001). 
 It is increasingly being recognized that Indians and other South 
Asians are an ethnic group at high risk for insulin resistance65. This is 
further compounded by large visceral fat, manifested by truncal obesity. 
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 Euglycemic – hyperinsulinemic clamp studies, the gold standard 
for insulin resistance experiments have shown South Asian men have 
shown to have lower glucose disposal rates per kg lean body mass as 
compared to Caucasian American66. For a similar BMI, Indian had 
higher truncal fat than Caucasian. International Diabetic Epidemiology 
group estimated that DM prevalence in Indians start increasing at BMI 
of 15 – 20 Kg/m2 compared with greater than 25kg/m2 in Chinese, 
Japanese and European Population. Thus Indians are at high risk for 
type 2 DM and metabolic syndrome. So there is a need to validate every 
conclusion of obesity research in Indian scenario. 
 Our effort is probably first in India to study the correlation 
between Insulin resistance and sex hormone binding globulin level in 
children. Our aim is restricted to find correlation between SHBG and 
insulin resistant indices only. If healthy correlation is found, it may be 
useful in our obesity clinic to serially follow the obese children without 
subjecting them into repeated fasting to determine insulin resistant 
status. 
             To fix cut off value for SHBG to determine insulin resistance, a 
study involving large sample size with cases and controls may be 
needed. 
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   We not only correlated SHBG level with fasting insulin level but 
also with epidemiological important derived indexes of insulin 
resistance like FGIR, HOMA-IR and QUICKI. 
a) There is significant negative correlation  found between sex 
hormone binding globulin levels and fasting insulin values.(r = 
-0.718679, p<0.01) 
b) The correlation between SHBG and fasting glucose insulin 
ratio is positive and significant (r =0.805667, p<0.01) 
c)         There is negative correlation between HOMA-IR  and SHBG 
              (r =-0.699214, p<0.01) 
d)       There is positive healthy correlation between SHBG and 
QUICKI which is better than correlation of SHBG with any other 
indices(r =0.922768, p<0.01). 
 Mehmet Keskin et al67 evaluated the usefulness of IR indexes in 
insulin resistant obese children. They conclude that a measure of insulin 
resistance among children and adolescents the  HOMA-IR is more 
reliable than FGIR and QUICKI. 
 Arie Katz, Sridhar S, Nambi et al68 performed Hyperinsulinemic 
euglycemic glucose clamp and minimal model FSIVGIT in 13 obese, 28 
non obese and 15 type 2 diabetic subjects. They correlated both HOMA-
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IR and QUICKI with the glucose clamp derived index of insulin 
sensitivity (SI clamp). The correlation between QUICKI and SI clamp is 
significantly better than correlation between HOMA and SI clamp (r = 
0.78 Vs r = - 0.60). 
 There is difference between adults and children in choosing better 
insulin index to assess insulin resistance. This may be partly explained 
by the fact that HOMA-IR is not linear over wide range of insulin 
sensitivity. In adult population, as type2 diabetes mellitus and glucose 
intolerance are common with elevated fasting insulin and glucose level, 
HOMA-IR is likely to correlate poorly with insulin resistance. Better 
correlation is found in children, as glucose intolerance and type2 
diabetes mellitus are rare. 
 When the distribution fasting insulin values is skewed, QUICKI 
correlates well with insulin resistance as it transforms the data by taking 
both logarithm and reciprocal of glucose – insulin product. 
 In our study we never conducted oral glucose tolerance test. There 
were no overt diabetic children. But there is skewed distribution of 
fasting insulin values with some children showing steep rise in fasting 
insulin levels without significant increase in fasting glucose level. This 
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may be the reason for better correlation between SHBG and QUICKI, 
when compared to one between SHBG and HOMA-IR. 
 Whatever may be the index used, there exists significant negative 
correlation between SHBG and hyperinsulinemia which reflects the 
physiological role played by insulin on SHBG secretion.  
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CONCLUSION 
 There is a strong negative correlation between SHBG and insulin 
resistant status. 
 Low SHBG concentration is  a stable integrated marker of insulin 
resistance and therefore has the characteristics to be potentially used as a 
surrogate measure of insulin resistance. 
 Currently it is cost effective and also avoids the ordeals of 
measuring fasting insulin indices. 
 For the time being the utility of SHBG estimation is limited to 
serial monitoring of insulin resistance in individuals on treatment after 
the presence of insulin resistance is established by conventional means. 
 An extensive study with large sample size with cases and control 
is needed to determine the cut off value of SHBG for insulin resistance. 
 With ethnic predisposition and drastic changes in life style there 
is spiralling incidence of metabolic syndrome in Indian population. 
Studies in the direction of searching such a useful surrogate marker of 
insulin resistance syndrome will have great impact in combating  this 
epidemic.  
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DATASHEET 
 
Serial no:                                                          Endo no:                               
Date: 
 
Name:                                                               Age:                                      
Sex: 
 
Address: 
 
                                         ANTHROPOMETRY 
 
Weight (kg):                     Height (m):      Body Mass Index (kg/m2):                     
         
 
 
                                   BIOCHEMICAL PARAMETERS  
 
 
Fasting Plasma Glucose(mmol/l)                  : 
 
Fasting Plasma Insulin(µu/ml)                      : 
 
Sex Hormone Binding Globulin(nmol/l)      :  
 
 
 
FASTING INSULIN INDICES 
 
        (Fasting Plasma Glucose(mmol/l)  X     Fasting Plasma Insulin(µu/ml)   
HOMA-IR: 
                                                                                 
      22.5        
 
 
:                                                                1                                                              
QUICKI   
                       (log fasting insulin(micromol/ml)+log fasting glucose(mg/dl)  
 
 
 
 
                      Fasting glucose  (mg/dl) 
FIGR      :                                 . 
                                                    Fasting Plasma Insulin (µu/ml) 
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